Global Journal of Medical Research, F: Diseases, Volume 23 Issue 2

13 Year 2023 Global Journal of Medical Research Volume XXIII Issue II Version I ( D ) F © 2023 Global Journals A Cancer Prevention and Treatment Opportunity Immunol . 1989; 26 (9): 851–57. doi.org/10.1016/ 0161-5890 (89)90141-7 27. Suzuki Y, Zeng Q, Alpert E. Isolation and partial characterization of a specific α -fetoprotein receptor on human monocytes. J. Clin. Invest . 1992; 90: 1530-1536. doi.org/10.1172/JCI116021 28. Sedky HA, Youssef SR, Gamal DA, Houssein HF, Elsalakawy WA. First report of the unique expression of RECAF (receptor for alfa feto-protein) in adult B- NHL/CLL patients. Blood Res. 2020; Dec 31; 55(4): 253-261. doi: 10.5045/br.2020.2020070 29. De Mees Ch, Laes J-F, Bakker J, Smitz J, Hennuy B, Van VoorenP, et al. Alpha-Fetoprotein Controls Female Fertility and Prenatal Development of the Gonadotropin-Releasing Hormone Pathway through an Antiestrogenic Action. Molecular and Cellular Biology. 2006; 26 (5): 2012–18. doi.org/10.1128/ MCB.26.5.2012-2018.2006 30. Jewett A, Kos J, Kaur K, Safaei T, Sutanto C, Chen W, Wong P, Namagerdi AK, Fang C, Fong Y, Ko MW. Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis. Mol Ther Oncolytics . 2019 Nov 29; 16: 41-52. doi: 10.1016/j.omto.2019.11.002 31. Tumino N, Besi F, Martini S, et al. Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity. Front. Immunol . 2022; 12: 803014. doi: 10.3389/fimmu.2021.803014 32. De Sanctis F, Adamo A, Canè S. et al. Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy. Semin Immunopathol (2022). doi.org/10.1007/s00281-022- 00965-1 33. Deutsch HF, Tsukada TS, Sasaki T, Hirai H. Cytotoxic Effects of Daunomycin-Fatty Acid Complexes on Rat Hepatoma Cells. Cancer Res. 198: 43 (6): 2668–2672.PMID: 6850584 34. Pak VN, Pak NA, Reshetnikov SS, Nikonov SD, Ogirenko AP. Method of treatment of malignant neoplasms and complex preparation having antineoplastic activity for use in such treatment. United States US6878688B2, filed June 20, 2001, issued April 12, 2005. https://patents.google.com/ patent/US6878688B2/en 35. Torres JM, Geuskens M, Uriel J. Receptor-Mediated Endocytosis and Recycling of Alpha-Fetoprotein in Human B-Lymphoma and T-Leukemia Cells. Int. J. Cancer . 1991; 47 (1): 110–117. doi.org/10.1002/ ijc.2910470120 36. Esteban C, Geuskens M, Uriel J. Activation of an Alpha-Fetoprotein (AFP)/Receptor Autocrine Loop in HT-29 Human Colon Carcinoma Cells. Int. J. Cancer . 1991; 49 (3): 425–430. doi.org/10.1002/ ijc.2910490320 37. Belyaev NN, Bogdanov AYu, Savvulidi PhG, et al. The influence of alpha-fetoprotein on natural suppressor cell activity and Ehrlich carcinoma growth. Korean J. Physiol. Pharmacol . 2008; (12): 193-197. doi: 10.4196/kjpp.2008.12.4.193 38. Zamorina SA, Shardina KY, Timganova VP, Bochkova MS, Uzhviyuk SV, Raev MB, Chereshnev VA. Effect of Alpha-Fetoprotein on Differentiation of Myeloid Supressor Cells. Dokl Biochem Biophys . 2021; 501(1): 434-437. doi: 10.1134/S16076729 21060077 39. Atemezem A, Mbemba E, Marfaing R, et al. Human AFP binds to primary macrophages. BBRC . 2002; 296: 507–514. doi.org/10.1016/S0006-291X( 02) 00909-9 40. de Oliveira CEC, Oda JMM, Guembarovski RL, de Oliveira KB, Ariza CB, Neto JS, et al. CC Chemokine Receptor 5: The Interface of Host Immunity and Cancer. Disease Markers , vol. 2014, Article ID 126954, 8 pages, 2014. doi.org/10.1155/2014/ 126954 41. Hawila E, Razon H, Wildbaum G, Blattner C, Sapir Y, Shaked Y, et al. CCR5 Directs the Mobilization of CD11b+Gr1+Ly6Clow Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development. Cell Reports. 2017; 21 (8): 2212–22 . doi.org/10.1016/j.celrep.2017.10.104 42. Ban Y, Mai J, Li X, et al. Targeting autocrine CCL5- CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity. Cancer Res . 2017; 77: 2857–68. doi:10.1158/0008-5472. CAN-16-2913 43. Zilio S, Bicciato S, Weed D, Serafni P. CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumor. J Immunother Cancer. 2022; 10(1): e003131. doi.org/ 10.1136/jitc-2021-003131 44. Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS. The Neonatal Fc Receptor (FcRn): A Misnomer? Front Immunol . 2019 Jul 10; 10: 1540. doi: 10.3389/fimmu.2019.01540 45. Blumberg R, Baker SK, Pyzik M, Gandhi A. Methods to manipulate alpha-fetoprotein (AFP). US0200031928 (2020). https://patents.google . com/patent/EP3148567A4/en 46. Thomas J, Torok MA, Agrawal K, Pfau T, Vu TT, Lyberger J, et al. The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer. International Journal of Molecular Sciences. 2022; 23(13): 7066. doi.org/ 10.3390/ijms23137066 47. Twafra S, Sokolik CG, Sneh T, et al. A novel Pyk2- derived peptide inhibits invadopodia-mediated breast cancer metastasis. Oncogene . 2022. doi.org/10.1038/s41388-022-02481-w 48. Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-Derived Suppressor Cells as a Therapeutic